Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine Glycaemic Variability in T2DM
NCT00272077Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2005
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Fasting Blood Glucose Coefficient of Variability. Started Apr 2005; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00272077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272077.